61.11 USD
▲+3.23+5.29%
盘后 59.48 +2.48%
2026-08-03
市值
$4.27B
市盈率
—
EPS
-1.65
股息率
—
52 周区间
14.79 – 59.72
成交量
2.53M
Beta
0.26
目标价
66.89
52W 低 14.7952W 高 59.72
价格走势
公司简介
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and othe...